Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 4/20 | 0.45 |
| ▸ | FNTB | P49356 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498408 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1USP2TSHRFNTA | |
| SCHEMBL3499404 | 0.90 | PPID (0.41) | ALDH1A1NPSR1TSHRFNTAFNTB | |
| SCHEMBL3499402 | 0.90 | PPID (0.41) | ALDH1A1NPSR1TSHRFNTAFNTB | |
| SCHEMBL3501304 | 0.87 | ALDH1A1 (0.44) | ALDH1A1NPSR1USP2TSHRFNTA | |
| SCHEMBL3501302 | 0.87 | ALDH1A1 (0.44) | ALDH1A1NPSR1USP2TSHRFNTA | |
| SCHEMBL3498868 | 0.83 | KMT2A (0.53) | MCL1KMT2AMEN1 | |
| SCHEMBL3498867 | 0.83 | KMT2A (0.53) | MCL1KMT2AMEN1 | |
| SCHEMBL3499197 | 0.80 | PPARA (0.44) | ALDH1A1MCL1KMT2APOLBMEN1 | |
| SCHEMBL3499201 | 0.80 | NAALAD2 (0.47) | MCL1KMT2AMEN1 | |
| SCHEMBL3500038 | 0.79 | PPID (0.38) | ALDH1A1NPSR1TSHRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | ALDH1A1 3047/4885NPSR1 101/4885USP2 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.